Abstract
Methods: Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4–8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test.
Results: Sarcoidosis in all patients improved significantly without any serious adverse reactions.
Conclusion: This study suggests that TNFα is effective in patients for whom conventional treatment fails.
Full Text
The Full Text of this article is available as a PDF (138.3 KB).